Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
85.85
+0.93 (1.10%)
Nov 21, 2024, 1:11 PM EST - Market open
Haemonetics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 28, 2024 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 | Apr '21 Apr 3, 2021 | Mar '20 Mar 28, 2020 | 2019 - 2015 |
| Revenue | 1,361 | 1,309 | 1,169 | 993.2 | 870.46 | 988.48 | Upgrade
|
| Revenue Growth (YoY) | 9.84% | 12.01% | 17.67% | 14.10% | -11.94% | 2.16% | Upgrade
|
| Cost of Revenue | 616.86 | 597.14 | 545.79 | 462.43 | 442.02 | 500.66 | Upgrade
|
| Gross Profit | 744.37 | 711.92 | 622.87 | 530.77 | 428.45 | 487.82 | Upgrade
|
| Selling, General & Admin | 431.16 | 420.82 | 373.95 | 332.2 | 263.83 | 266.33 | Upgrade
|
| Research & Development | 57.91 | 52.23 | 49.08 | 45.98 | 31.69 | 30 | Upgrade
|
| Operating Expenses | 531.13 | 505.08 | 455.67 | 425.6 | 328.35 | 322.08 | Upgrade
|
| Operating Income | 213.24 | 206.84 | 167.2 | 105.17 | 100.1 | 165.75 | Upgrade
|
| Interest Expense | -15.11 | -19.5 | -13 | -5.8 | -9.4 | -13.5 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.63 | 1.51 | - | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 4.97 | 4.97 | -1.63 | -11.32 | -4.43 | -2.7 | Upgrade
|
| EBT Excluding Unusual Items | 204.72 | 193.82 | 152.57 | 88.05 | 86.26 | 149.55 | Upgrade
|
| Merger & Restructuring Charges | -42.87 | -33.54 | -11.55 | -28.82 | -25.26 | -19.88 | Upgrade
|
| Gain (Loss) on Sale of Assets | 2 | 2 | 0.38 | 9.6 | 32.81 | 8.08 | Upgrade
|
| Asset Writedown | -10.42 | -10.42 | - | -5.2 | -20.9 | -50.6 | Upgrade
|
| Pretax Income | 158.86 | 151.87 | 141.4 | 63.63 | 72.91 | 87.15 | Upgrade
|
| Income Tax Expense | 35.05 | 34.31 | 26 | 20.25 | -6.56 | 10.63 | Upgrade
|
| Net Income | 123.81 | 117.56 | 115.4 | 43.38 | 79.47 | 76.53 | Upgrade
|
| Net Income to Common | 123.81 | 117.56 | 115.4 | 43.38 | 79.47 | 76.53 | Upgrade
|
| Net Income Growth | -3.48% | 1.87% | 166.05% | -45.42% | 3.85% | 39.09% | Upgrade
|
| Shares Outstanding (Basic) | 51 | 51 | 51 | 51 | 51 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 51 | 51 | 51 | 51 | 51 | 52 | Upgrade
|
| Shares Change (YoY) | 0.23% | -0.04% | 0.13% | 0.12% | -1.01% | -2.13% | Upgrade
|
| EPS (Basic) | 2.43 | 2.32 | 2.27 | 0.85 | 1.57 | 1.51 | Upgrade
|
| EPS (Diluted) | 2.41 | 2.29 | 2.24 | 0.84 | 1.55 | 1.48 | Upgrade
|
| EPS Growth | -3.24% | 2.23% | 166.67% | -45.81% | 4.73% | 42.31% | Upgrade
|
| Free Cash Flow | 31.12 | 115.46 | 162.87 | 75.75 | 71.77 | 109.46 | Upgrade
|
| Free Cash Flow Per Share | 0.61 | 2.25 | 3.17 | 1.48 | 1.40 | 2.11 | Upgrade
|
| Gross Margin | 54.68% | 54.38% | 53.30% | 53.44% | 49.22% | 49.35% | Upgrade
|
| Operating Margin | 15.66% | 15.80% | 14.31% | 10.59% | 11.50% | 16.77% | Upgrade
|
| Profit Margin | 9.10% | 8.98% | 9.87% | 4.37% | 9.13% | 7.74% | Upgrade
|
| Free Cash Flow Margin | 2.29% | 8.82% | 13.94% | 7.63% | 8.24% | 11.07% | Upgrade
|
| EBITDA | 314.16 | 295.45 | 252.01 | 191.72 | 184.38 | 257.93 | Upgrade
|
| EBITDA Margin | 23.08% | 22.57% | 21.56% | 19.30% | 21.18% | 26.09% | Upgrade
|
| D&A For EBITDA | 100.92 | 88.62 | 84.81 | 86.55 | 84.29 | 92.19 | Upgrade
|
| EBIT | 213.24 | 206.84 | 167.2 | 105.17 | 100.1 | 165.75 | Upgrade
|
| EBIT Margin | 15.66% | 15.80% | 14.31% | 10.59% | 11.50% | 16.77% | Upgrade
|
| Effective Tax Rate | 22.06% | 22.59% | 18.39% | 31.83% | - | 12.19% | Upgrade
|
| Advertising Expenses | - | 7.1 | 7.2 | 4.4 | 2.7 | 4.3 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.